Product logins

Find logins to all Clarivate products below.


Type 2 Diabetes | Treatment Algorithms: Claims Data Analysis | US | 2024

Metformin is the most heavily prescribed type 2 diabetes (T2D) drug and dominates the early lines of therapy before disease progression requires insulin replacement. The emergence of more-effective, safer, and better-tolerated therapies, such as sodium-glucose cotransporter 2 (SGLT- 2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) agonists, has provided physicians with a broad array of therapeutic options. Moreover, with a better understanding of T2D and its complications, treatment of the disease is becoming more individualized. Numerous branded agents from both established and recently launched classes are now jostling for position in the treatment paradigm.

Questions answered

  • What patient shares do key therapies garner by line of therapy in newly diagnosed T2D patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed T2D patients?
  • How have Brenzavvy and Mounjaro been integrated into the treatment algorithm, and what are their sources of business?
  • What percentage of T2D patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of T2D patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

Markets covered: United States

Key drugs: Humalog, Jardiance, Lantus, metformin, Mounjaro, Novolog, Ozempic, Rybelsus, Toujeo, Trulicity

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Key feature

Dashboard featuring interactive visuals, easy navigation, and expanded analyses

Related Market Assessment Reports

Report
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (US)
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAAD) is a rare autoimmune inflammatory CNS disorder defined by IgG antibodies targeting the myelin oligodendrocyte glycoprotein…
Report
Obesity – Current Treatment – Treatment Algorithms: Claims Data Analysis – Obesity (US)
GLP-1 RA products have set new standards for weight-loss drugs and are driving the rapid growth of the obesity market. Novo Nordisk’s semaglutide (Wegovy) and Eli Lilly’s tirzepatide (Zepbound…
Report
Painful Diabetic Neuropathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Painful Diabetic Neuropathy (US)
Painful diabetic neuropathy (PDN) is a prevalent complication of diabetes, typically causing persistent burning, tingling, or sharp pain in the extremities. Management relies on a range of…
Report
Bipolar Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Bipolar Disorder (US)
Bipolar disorder (BPD) is a chronic condition characterized by recurrent episodes of aberrant mood, with patients experiencing manic, depressive, or mixed symptoms between periods of stable mood…
Report
Type 1 Diabetes – Current Treatment – Treatment Algorithms: Claims Data Analysis – Type 1 Diabetes (US)
Intensive insulin regimens have proven effective in delaying the progression of complications associated with untreated or poorly treated type 1 diabetes (T1D). Thus, insulins remain the…